Remegen Co Ltd (9995)

Hong Kong
Currency in HKD
13.06
+0.44(+3.49%)
Closed
9995 Scorecard
Full Analysis
Analysts anticipate sales growth in the current year
Fair Value
Day's Range
12.3613.58
52 wk Range
10.2034.45
Key Statistics
Edit
Bid/Ask
13.04 / 13.06
Prev. Close
12.62
Open
12.82
Day's Range
12.36-13.58
52 wk Range
10.2-34.45
Volume
2.25M
Average Volume (3m)
2.29M
1-Year Change
-45.13%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
9995 Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
24.98
Upside
+91.28%
Members' Sentiments
Bearish
Bullish
ProTips
Impressive gross profit margins
Show more

Remegen Co Ltd Company Profile

RemeGen Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in Mainland China and the United States. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus (SLE) an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. Its products in various stages of development include RC18, which is under phase III clinical trials for the treatment of neuromyelitis optica spectrum disorder and rheumatoid arthritis, and phase II clinical trials for the treatment of IgA nephritis, Sjögren’s syndrome, multiple sclerosis, and myasthenia gravis; RC28, which has completed Phase 1 clinical trials for use in the treatment of wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy; RC98, a PD-L1 monoclonal antibody for the treatment of solid tumors and is under Phase I clinical trial; RC88, which is in Phase 1 clinical trials for use in the treatment of mesothelioma, bile duct carcinoma, pancreatic cancer, ovarian carcinoma, lung adenocarcinoma, and other solid tumors; and RC108 that is in Phase 1 clinical trials to treat various solid tumors. In addition, the company’s products under pre-clinical development include RC118, RC138, RC148, RC158, and RC198 to treat various solid tumors; and RC218 and RC228 to treat ophthalmopathy. The company was founded in 2008 and is headquartered in Yantai, the People’s Republic of China.

Compare 9995 to Peers and Sector

Metrics to compare
9995
Peers
Sector
Relationship
P/E Ratio
−7.7x−10.2x−0.6x
PEG Ratio
0.46−0.020.00
Price/Book
5.0x1.7x2.6x
Price / LTM Sales
7.8x2.8x3.1x
Upside (Analyst Target)
69.5%34.0%54.6%
Fair Value Upside
Unlock16.5%7.7%Unlock

Analyst Ratings

12 Buy
4 Hold
0 Sell
Ratings:
16 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 24.98
(+91.28% Upside)

Earnings

Latest Release
-
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

FAQ

What Is the Remegen (9995) Stock Price Today?

The Remegen stock price today is 13.06

What Stock Exchange Does Remegen Trade On?

Remegen is listed and trades on the Hong Kong stock exchange.

What Is the Stock Symbol for Remegen?

The stock symbol for Remegen is "9995."

What Is the Remegen Market Cap?

As of today, Remegen market cap is 12.65B.

What is Remegen Earnings Per Share?

The Remegen EPS is -2.88.

From a Technical Analysis Perspective, Is 9995 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.